Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Subscriber?
Search

July 2026

How Specialty Diagnostic Tests Connect with Lab Customers – 2

TDR Insider /

 In this exclusive Q&A, Revvity’s Yves Dubaquie provides details about the in vitro diagnostics company’s priorities, including developing specialty tests and reviewing its business in China. Dubaquie also explains why clinical laboratories may need to consider hiring more technology-savvy workers in the future as the complexity of instruments grows. Yves Dubaquie, PhD, is a 30-veteran […]

To access this post, you must purchase The Dark Report.

How Specialty Diagnostic Tests Connect with Lab Customers – 2 Read More »

Hospice Fraud Crackdown Serves as Warning

Lab Risk & Compliance /

CEO SUMMARY: Hospice providers were swept into a broad Medicare fraud enforcement effort, and some compliant centers got suspended from Medicare, according to The Washington Post. It’s reasonable to conclude small laboratories could face similar scrutiny during future genetic testing investigations. Legitimate hospice providers across California recently found themselves suspended from Medicare—not because investigators had

To access this post, you must purchase The Dark Report.

Hospice Fraud Crackdown Serves as Warning Read More »

How Specialty Diagnostic Tests Connect with Lab Customers

IVD/Lab Informatics /

CEO SUMMARY: In this exclusive Q&A, Revvity’s Yves Dubaquie provides details about the in vitro diagnostics company’s priorities, including developing specialty tests and reviewing its business in China. Dubaquie also explains why clinical laboratories may need to consider hiring more technology-savvy workers in the future as the complexity of instruments grows. Editor’s note: Yves Dubaquie,

To access this post, you must purchase The Dark Report.

How Specialty Diagnostic Tests Connect with Lab Customers Read More »

What Earnings Calls Reveal about Shifting IVD Pipelines

IVD/Lab Informatics /

CEO SUMMARY: An examination of recent earnings reports from the top global in vitro diagnostics (IVD) companies uncovers three macro-trends that clinical laboratories should monitor. Among those trends are continuing pressure from China’s volume-based procurement reforms, a milder-than-expected demand for respiratory testing earlier this year, and the war in Iran. Expect IVD firms to attempt

To access this post, you must purchase The Dark Report.

What Earnings Calls Reveal about Shifting IVD Pipelines Read More »

July, 2026, Intelligence

Lab Intelligence /

Novel Therapies, Clinical Lab Impact Novel therapies discussed at the ELRIG Drug Discovery USA 2026 conference could eventually create new opportunities—and new challenges—for clinical laboratories as more targeted treatments move toward routine clinical use. Speakers highlighted emerging approaches such as molecular glues, targeted protein degradation, and other precision therapies designed to act on disease-causing proteins

To access this post, you must purchase The Dark Report.

July, 2026, Intelligence Read More »

Polling Data Shows Cracks in Medical Necessity Compliance

Lab Risk & Compliance /

CEO SUMMARY: Data gathered from three separate events consistently points to a common problem in clinical laboratories: Nearly one-third of respondents indicated their organizations do not review medical necessity of diagnostic tests, and another 29% were not sure. Experts say those answers should spur all laboratories to audit their compliance efforts given the federal government’s

To access this post, you must purchase The Dark Report.

Polling Data Shows Cracks in Medical Necessity Compliance Read More »

Compliance Complacency Must Instead Become a Mandate for Action in Clinical Labs

Commentary and Opinion by R. Lewis Dark /

The collective complacency currently permeating our industry regarding medical necessity compliance is nothing short of a ticking bomb. For years, too many clinical laboratory leaders have treated compliance as a secondary paperwork exercise, insulated by the assumption that if a physician signs a test requisition, the lab is absolved of risk. That delusion is about

To access this post, you must purchase The Dark Report.

Compliance Complacency Must Instead Become a Mandate for Action in Clinical Labs Read More »

Consortium Brings Open- Source Vision to Digital Pathology

Digital Pathology /

CEO SUMMARY: American health technology company Tempus AI, in concert with two academic medical centers, recently formed a consortium that will offer a free, open-source digital pathology platform. The organizations hope to develop open standards that will increase the interoperability of digital pathology systems while also making the technology more accessible for resource-strapped pathology practices.

To access this post, you must purchase The Dark Report.

Consortium Brings Open- Source Vision to Digital Pathology Read More »

;